For more information about this Blicy and other policies regarding dual use research of concern, visit the U.S. Governmer&cienceSafety Security(S3) website at <a href="http://www.phe.gov/s3/dualuse">http://www.phe.gov/s3/dualuse</a>

All provisions in this Policy supersede those contain **etabip** revious draftpolicypublished on February 22, 2013 (Federal Register 78 (36): 123/2972) This Policy and the nited States Government Policy for Oversight of Life Sciences Dual Use Research of Conditient was released March 29/2012 (

## United States Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern

## Contents

<u>^ š]}v /ív≫š Œ</u> } μ š]}v	
Section 2. Purpose	5
Section 3. Guiding Principles for Oversight of Laifenses Dual Use Research	5
Section 4. Definitions	6
Section 5. Policytatement	7
Section 6. Applicability of this Policy and Scop@voefrsight of DURC	
6.1. Applicability	
6.2. Scope of Research Requiring Oversight	
6.2.1. Agents and toxins	
6.2.2. Categories of experiments	9
6.3. Compliance	—
Section 7. Organizational Framework for Oversight of DURC	—
7.1. Responsibilities of Principal/estigators	
7.2. Responsibilities of USGneded Research Institutions	
7.3. Responsibilities of USG Funding Agencies	
7.4. Responsibilities of the USG	
Section 8. Resources for Institution@versight of DURC	

This Policy,the "United States Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern," addresses institutional oversight of DURC. Oversight includes transfer of biological agents and toxins that have the potential to pose a severe risk to public health and safety, animal and plant health or animal and plant prod**octs**; povisions of the select agent regulations found at 42 CFR Part 73, 9 CFR Part 121, and 7 CFR P, and 30 the export control regulations at 5 CFR Parts 73074 (known as the Export Administration Regulations (EAR), and 22 CFR Parts 1200 (known as the "International Traffic in Arms Regulations (TAR). Note that the term "dual use" should not be interpreted to indicate which regulations goern the export of these items, and that agents of the DURC agents/experiments are controlled by the ITAR nd not the EAR

This Policy will take effect of eptember 24, 201,5 which is 12 months after its rele not benv001 T0(e)-1(d)

- D. Oversight of DURC must recognize both the need for security and the need for research progress; as such, the degree of oversight should be commenswith the possible consequences of misuse.
- E. Effective oversight helps maintain public trust in the life sciences research enterprise by demonstrating that the scientific community recognizes the implications of DURC and is acting responsibly to protect public welfare and **see**vesecurity.
- F. USGagencies that fund DURC, the recipients of those public funds, and individuals who conduct this research share the oversight responsibility.
- G. It is essential to have a consistent approach to the oversight of DURC.
- H. Any oversight process for DURC should be periodically evaluated both for effectiveness and impact on the research enterprise.
- I. The free and open conduct and communication of life sciences research is vital to a robust scientific enterprise and will continue to be the **gofathe USG**. It also should continue to be the goad institutions engaged in life sciences research.
- J. Educating the scientific community about the dual use potential of life sciences research and cultivating a sense of responsibility for dual use research among life scientists is essential for promoting responsible research behavior.
- K. No policy or set of guidelines can anticipate every possible situation. Motivation, awareness of the dual use issue, and good judgment are key considerations in the responsible evaluation of research for dual use potential. It is incumbent on those engaged in life sciences research to adhere to the intent of this Policy as well as to the performance standards described herein.

## Section 4. Definitions

For the purpose of the following terms are defined

- A. "To certify" is to attest to the USG that an institution subject to this Policy will comply with all aspects of this Policy.
- B. "Dual use research" is research conducted for legitimate purposes that generates knowledge, information, technologies, and/or products th**atut**d be utilized for both benevolentand harmful purposes.
- C. "Dual use research of concernDURC)s life sciences research that, based on current understanding, can be reasonably anticipated to provide knowledge, information, products, or technologies that could be directly sapplied to pose a significant threat

with broad potential consequences **poublic** health and safety, agricultural crops and other plants, animals, the environment, materiel, or national security.

- D. "Institution" is any governmentagency (Federal, Statteibal, or local), academic institution, corporation, company, partnershipociety, association, firm, sole proprietorship, or other legal entity conducting research.
- E. "Institutional Contact for Dual Use Research CDUR is an individual designated by the institution to serve as an institutional point of contact for questiones and compliance with and implementation of the requirements for the oversight of DURC as well as the liaison (as necessary) between the institution and the relevant for agency.
- F. "Institutional Review Entity" (IRE)s a committee established by the institutionas described in Section 7.2.E and empowered to execute the requirements in Section 7.2.B.i iii, v, and viii.
- G. "Life sciences" pertains to living organisms (e.g., microbes, human beings, animals, and plants) and their products, including all disciplines and methodologies of biology such as aerobiology, agricultural science, plant science, animal science, bioinformatics, genomics, proteomics, nicrobiology, synthetic biology, virology, molecular biology, environmental science, public health, modeling, engineering of living systems, and all applications of the biological sciences. The term is meant to encompass the diverse approaches to understanding life at the level of ecosystems, populations, organisms, organs, tissues, cells, and molecules.
- H. "National Societical (And)-4 (and)-4 (and)-23(0) and (no base of the solution of the soluti

## 6.2.1. Agents and toxins

- a) Avian influenza virus (highly pathogenic)
- b) Bacillus anthracis
- c) Botulinum neurotoxinh
- d) Burkholderia mallei
- e) Burkholderia pseudomallei
- f) Ebola virus
- g) Foot-and-mouth disease virus
- h) Francisella tularensis
- i) Marburg virus
- j) Reconstructed 1918 Influenziarws
- k) Rinderpest virus
- I) Toxinproducing strains of Clostridium botulinum
- m) Variola major virus
- n) Variola minor virus
- o) Yersinia pestis
- 6.2.2. Categories of experiments
  - a) Enhances the harmfurtifacesMC BT /LB0(C Bh(2.)B44 Tm 0 0.53 20)2(f)10(t)10(he)3(a)
  - c)

<sup>&</sup>lt;sup>5</sup> The 15 agents and toxins listed in this Policy are subject to the select **æggehati**ons(42 CFR Part 73, 7 CFR Part 331, and 9 CFR Part 12th/hich set forth the requirements for possession, use, and transfer of select agents and toxins, and have the potential to pose a severe threat to human, animal, or plant health, or to animal or plant products. It is important to note, however, that the Federal Select Agent Programs not oversee the implementation of this Policy or the March 2012 DURC Policy.

<sup>&</sup>lt;sup>6</sup> For the purposes of this Policy, there are no exempt quantities of botulinum neurotoxin. Research involving any quantity of botulinum neurotoxin should be evaluated for DURC potential.

research,and may subject the institution to

will receive the notification for administrative purpose and will inturn refer the notification to an appropriate gency based upon the nature of the research.

- F. For institutions subject to this Policy, certify that the institution will comply with this Policy.
- G. Oversight by USG unding agencies and the USG as articulated in Maech 2012 DURC Policy with additional responsibilities with respect to this Policy described in Second and 7.4 below.

Figure 1 provides an overview of the process for institutioned iew of life sciences research within the scope of the PolicyH2

The PI's research with one or more of the agents or toxins listed in Section
6.2.1 also producesims to produce r can be reasonably anticipated to produce one or more of the seven ef

undergo steps 7.2. Bvii, but will be subject to ongoing review and notification

the PI) responsible for the performance of the DURC description of the IRE's basis for its determination

v. Identification by the IRE of the anticipated benefits of the research identified

D. Designate an Institutional Contact for Dual Use Research (ICDUR) to serve as a institutional point of contact for questionsegarding compliance with and

- G. Provide education and training on DURC for individuals conducting life sciences researchwith one or more of the agents listed in Section 6.2f. this Policy, and maintain records of such education and training for the term of the research grant or contract plus three years after its completion. Institutions may also wish to address dual use topics in existing courses on research ethics or the responsible conduct of researchInstitutions may require additional recordepingand should designate an individuatesponsible for maintairing documentation.
- H. Ensure compliance with the solicy and with approved risk mitigation plans. Report

7.3. Responsibilities of USG unding Agencies

- A. Develop training tools and materials for use by the USG agencies yamstitutions implementing this Policy.
- B. Provide education and outreach to stakeholders about dual use policies and issues.
- C. Provide guidance to institutions on the shariorfgDURC research products and on the communication of DURC.
- D. Conveneadvisory bodies such as NSABS necessary develop reBR0(

- i. TheIRErequires guidance on developing an adequate risk mitigation plan in cases where the potential risks are perceived as particularly high;
- ii. TheIREconsiders the only viable risk mitigation measure to be not conducting or not communicating the research in question;
- iii. The PI does not agree with the finding of the **aRE** so the institution would like to request outside advice;
- iv. The research in question represents a particularly complex case or appears to fall outside thescope of this Policy, but still seems to present significant concerns; or
- v. Guidance is required to ensure a clear **enst** anding of how the USiG terprets the definition of DURC and related terms.